export default function AdipotideOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Adipotide is an experimental research compound designed to destroy fat tissue by cutting off its blood supply. In a single primate study, it produced dramatic fat loss — but also caused significant kidney damage. It has never been tested in a completed human trial and has no established human dose, no pharmaceutical-grade formulation, and no safety data in people. Community use represents uncontrolled human experimentation.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person — Heard about a peptide that &ldquo;melts fat&rdquo; and wants to understand what it actually is</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I saw this described as a fat-targeting peptide that makes fat tissue literally die. Is this real? It sounds incredible — why isn&rsquo;t everyone using it?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The monkey study results were genuinely dramatic</strong><br />In the single published primate study, obese monkeys lost about 11% of their body weight and 27% of abdominal fat in four weeks. That is a striking result. When something produces that kind of number in an animal study, it gets attention — and the attention is understandable.</li>
          <li><strong>The concept of directly eliminating fat cells is appealing</strong><br />Most weight loss approaches work through appetite, metabolism, or calorie restriction — indirect levers. Adipotide&rsquo;s proposed mechanism — physically destroying the blood vessels that keep fat tissue alive — is a fundamentally different approach. The idea of going directly after the fat tissue itself is viscerally compelling.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The same primate study that showed dramatic fat loss also documented serious kidney damage in the monkeys — elevated kidney injury markers and visible tissue damage on pathology. That damage partially recovered after the drug was stopped, but it was real. There has never been a completed human safety trial. No one knows what dose is safe in people, whether it even works the same way in humans, or whether the kidney targeting seen in monkeys would be worse or better. Community use means injecting a research chemical with no pharmaceutical manufacturing standards, no verified concentration, no sterile preparation, and no established safe dose. Net: this is a pre-clinical compound where the animal data includes a serious safety signal that has never been resolved in humans. Curiosity is understandable; use is a different matter entirely.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete — Interested in aggressive body composition tools for cutting phases</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve tried everything for stubborn fat. If something actually targets and destroys fat vasculature, that sounds like exactly what a cutting phase needs. What&rsquo;s the actual risk profile?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>A local fat-destruction mechanism with no appetite suppression needed</strong><br />Athletes on aggressive cuts often struggle with energy and training performance when using appetite-suppressing drugs. If Adipotide worked as a direct fat-destroying mechanism without touching hunger hormones or cortisol, it would represent a pharmacologically clean approach to the cutting problem — no performance impact, just fat reduction.</li>
          <li><strong>The targeting concept suggests regional fat reduction could be possible</strong><br />The mechanism — targeting proteins specifically expressed on fat tissue vasculature — theoretically means the damage is concentrated in fat, not systemic. An athlete with stubborn regional fat (lower abs, lower back) would find the concept of tissue-targeted treatment extremely appealing.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The targeting is not as clean as the theory suggests. In the monkey study, the compound also damaged kidney vasculature — kidneys are high-performance organs with their own specialized blood vessel types, and the selectivity of Adipotide&rsquo;s targeting domain was not clean enough to avoid them. For an athlete who depends on kidney function for hydration management, training recovery, and drug clearance from other compounds, kidney damage is not a tolerable side effect. There is also no data on what happens with repeated use, no established recovery protocol if kidney injury occurs, and no legitimate supply chain. Net: the concept is interesting but the safety signal in the only relevant study is a kidney toxicity outcome that has never been addressed in humans — that is not a risk worth taking for body composition goals that can be addressed through other means.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker — Interested in novel fat loss mechanisms and the science of targeted cell killing</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;The design here — a bifunctional peptide with a targeting domain and a pro-apoptotic effector domain — is genuinely novel engineering. What does the actual pharmacology tell us about why the primate study worked and why human development stalled?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The chimeric peptide engineering is genuinely sophisticated</strong><br />Adipotide is a two-domain construct: one end targets a protein overexpressed on fat tissue blood vessels, and the other end contains a mitochondria-disrupting sequence that kills the cells it reaches. This &ldquo;guided missile&rdquo; design — a targeting vector linked to a cytotoxic payload — is the same conceptual approach used in some cancer immunotherapy research. It represents real innovation in peptide engineering.</li>
          <li><strong>Prohibition on targeting vasculature raises interesting selectivity questions</strong><br />The fact that kidney vasculature was also hit speaks to a fascinating unsolved problem in targeted drug delivery: how do you achieve truly tissue-selective targeting when different tissues share surface protein expression patterns? Adipotide&rsquo;s failure to achieve clean selectivity is informative about the difficulty of this class of approach, not just a safety footnote.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Clinical development appears to have stalled, and the likely reason is the renal toxicity signal combined with the selectivity problem. Even if a developer wanted to move forward, the kidney damage in the primate study would require demonstrating a clean therapeutic window in humans — a high bar for an elective fat loss indication where safer alternatives exist. Community interest has kept this compound circulating as a research chemical, but research chemical sourcing means no quality control, no verified sequence, no sterile formulation, and no way to know what concentration you actually have. The intellectual appeal of the mechanism is real. The practical conclusion is that Adipotide represents an interesting dead end in targeted adipose intervention — important for understanding what this approach requires, not viable for personal use given where the science actually stands. Net: worth understanding as a case study in targeted delivery; not worth using when human safety has never been established and the animal data includes a serious organ toxicity finding.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Adipotide is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not a drug — no human clinical trials completed, no approved use</li>
              <li>Not safe by default — the one meaningful animal study documented serious kidney toxicity</li>
              <li>Not a selective fat destroyer — kidney vasculature was also affected in primates</li>
              <li>Not available in pharmaceutical-grade form — research chemical only</li>
              <li>Not something with an established human dose, protocol, or safety monitoring framework</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>Novel bifunctional peptide design — a targeting domain plus a cell-killing effector domain in one molecule</li>
              <li>The primate fat loss results were among the most dramatic published for any single compound in that model</li>
              <li>Illustrates the unsolved selectivity challenge in targeted vascular pharmacology</li>
              <li>Mechanistically distinct from every other fat-loss approach — works on blood supply rather than appetite or metabolism</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
